Announcement
Within the framework of informing the investment public we would like to note the following:
1. As announced on 17 November 2006, Euromedica has selected the company with the corporate name Lazard as its financial consultant, which has undertaken the task of finding suitable investors willing to invest approximately 100 million Euros in the company?s share capital increase.
The revenues from the forecasted share capital increase will be used:
- to construct a hospital in Athens, with which the company will seek to collaborate with another group of companies and/or prominent physicians.
- to further expand the company?s already broad network through the buy-out of diagnostic centres throughout Greece. The company has already found and is currently holding talks with medical clinics for possible future collaboration.
2. In addition, Euromedica is currently in the stage of advanced negotiations regarding the complete incorporation of its subsidiary companies, the General Clinic of Thessalonica (32.58% is held by Axon Holdings), the Medical Institute of Advanced Technology of Crete (39.05% is held by Axon Holdings) and Euromedica of Western Macedonia, therein.
3. Euromedica will proceed in the exploitation of a corner real estate that is located in a preferential location along Siggrou ave, of an area of approximately 1,350 square metres, on which a five-floor building of a total area of 2,900 square metres and a underground six-floor parking area of a total area of approximately 2,300 square metres have been erected.
4. Concurrently, Euromedica is examining the possibility of exploiting its assets, of a value exceeding 120 million Euros (in 2003 prices), through the establishment of a property development company of Law 2778/99 (Real Estate Investment Company), in order to better segregate the business risk of real estates from that associated with the provision of health services. Pursuant to the Law, the said real estate investment company will be listed on the Athens Stock Exchange in order to draw capital, which will be used for its further growth.